Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) (ROCITP2)
Prospective Study Assessing the Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism
Pregnant women with a prior history of venous thromboembolism (VTE) are at increased risk of recurrent VTE. Current guidelines assessing the role of prophylaxis in pregnant women with prior VTE are based primarily on expert opinion and the optimal clinical management strategy remains unclear.
This multicentre, prospective cohort study aims to test the following hypotheses:
- Antepartum prophylaxis with fixed-dose low molecular-weight heparin (LMWH) is safe, convenient and associated with an acceptably low risk of recurrent VTE in women with a single prior episode of VTE that was either unprovoked or associated with a minor transient risk factor. (Moderate risk cohort)
- Withholding antepartum prophylaxis is safe (recurrence risk <1%) in pregnant women with a single prior episode of VTE provoked by a major transient risk factor. (Low risk cohort)
All study patients will receive 6 weeks of postpartum prophylaxis.
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Shannon M Bates, MD
- Telefonnummer: 73928 905-521-2100
- E-mail: batesm@mcmaster.ca
Undersøgelse Kontakt Backup
- Navn: Nancy Lloyd, MSc
- Telefonnummer: 33269 905-522-1155
- E-mail: lloydn@mcmaster.ca
Studiesteder
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare Hamilton
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster University Medical Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Confirmed pregnancy (positive serum or urine)
- At least 18 years of age
- History of one prior episode of VTE consisting of DVT (diagnosed by compression ultrasonography [CUS] or venography) and/or PE (diagnosed by ventilation-perfusion [V/Q] lung scintigraphy, computed tomographic pulmonary angiography [CTPA], or traditional pulmonary angiography)
Exclusion Criteria:
- Ongoing need for therapeutic anticoagulation for prevention or treatment of cardioembolic stroke
- Known high-risk thrombophilia (specifically antithrombin deficiency, protein S deficiency, protein C deficiency, homozygosity for the factor V Leiden or prothrombin G20210A mutations, antiphospholipid antibody or compound abnormalities)
- VTE within 3 months of the current pregnancy
- Clinical risk factor for initial episode of VTE, if present, not resolved (excluding pregnancy)
- Known contraindication to anticoagulation (including active, uncontrolled bleeding or major bleed within the previous 4 weeks)
- For patients with prior unprovoked VTE, contraindication to LMWH (including allergy, HIT, impaired renal function, osteoporosis)
- Geographic or social factors precluding follow-up
- Inability or unwillingness to provide informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Prior VTE minor transient risk factor
Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
|
|
Prior VTE major transient risk factor
Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Symptomatic venous thromboembolism
Tidsramme: antepartum period (expected average 7 months)
|
Symptomatic objectively confirmed recurrent VTE, including proximal DVT, non-fatal PE, and fatal PE during antepartum period
|
antepartum period (expected average 7 months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Symptomatic recurrent venous thromboembolism
Tidsramme: antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic recurrent VTE antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
|
Symptomatic recurrent pulmonary embolism
Tidsramme: antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic objectively confirmed recurrent PE antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
|
Thrombocytopenia or heparin-induced thrombocytopenia (HIT)
Tidsramme: antepartum period (expected average 7 months)
|
Thrombocytopenia or HIT during antepartum period
|
antepartum period (expected average 7 months)
|
|
Symptomatic osteoporosis
Tidsramme: antepartum period (expected average 7 months) and first 3 months postpartum
|
Symptomatic osteoporosis antepartum and within first 3 months postpartum
|
antepartum period (expected average 7 months) and first 3 months postpartum
|
|
Other complications
Tidsramme: antepartum (expected average 7 months) and within first 3 months postpartum
|
Other complications sufficient to stop treatment (e.g., local and systemic reactions) antepartum and within first 3 months postpartum
|
antepartum (expected average 7 months) and within first 3 months postpartum
|
|
Pregnancy complications and outcomes
Tidsramme: antepartum period (expected average 7 months)
|
Pregnancy complications and outcomes including fetal death, pre-eclampsia, toxemia, intrauterine growth restriction, prematurity during antepartum period
|
antepartum period (expected average 7 months)
|
|
Fetal anomalies
Tidsramme: antepartum (expected average 7 months) and during first 3 months postpartum
|
Fetal anomalies
|
antepartum (expected average 7 months) and during first 3 months postpartum
|
|
Major and minor bleeding
Tidsramme: antepartum (expected average 7 months)
|
Major and minor bleeding
|
antepartum (expected average 7 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Shannon M Bates, MD, McMaster University Medical Centre
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HHS130511
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .